摘要
肝癌目前治疗的方法以外科切除和介入治疗为主,其中TACE已成为治疗中晚期不可切除肝癌的首选方法。载药微球作为一种新型栓塞材料,已广泛用于肝癌的TACE治疗,具有一定的安全性和有效性。与传统栓塞方法相比,载药微球能够降低全身化疗药物浓度、提高局部肿瘤药物浓度、延长药物作用时间、提高肿瘤的反应率,进而降低肿瘤的复发率、缩短住院时间、延长患者生存期。但载药微球的使用方法、术者操作技术,化疗药物的载入饱和量等差异,都可能对治疗结果产生影响。因此,载药微球的使用规范与治疗肝细胞癌的安全性与疗效,值得进一步研究。
At present,surgical resection and interventional therapy are the main methods for the treatment of hepatocellular carcinoma(HCC),and transcatheter arterial chemoembolization(TACE)has become the first choice for the treatment of advanced unresectable HCC.As a new type of embolization material,drug-eluting beads has been widely used in the treatment of HCC with TACE,and the drug-eluting beads carries certain safety and effectiveness.Compared with the traditional embolization methods,the use of drugeluting beads can reduce the systemic concentration of chemotherapeutic drugs,increase the concentration of drugs within local tumors,prolong the time of action of drugs,and improve the response rate of tumor,and thus reduce the recurrence rate of tumors,shorten the hospitalization time,and prolong the survival time.However,the use-method of drug-eluting beads,the operator’s manipulation skill,and the loading saturation of chemotherapeutic drugs may have an impact on the outcome of the treatment.Therefore,the specification for the use of drug-eluting beads,as well as the safety and efficacy of microspheres in the treatment of HCC,are worthy of further study.
作者
翟越
赵卫
潘文秋
张雪平
陆孜
李红
胡继红
ZHAI Yue;ZHAO Wei;PAN Wenqiu;ZHANG Xueping;LU Zi;LI Hong;HU Jihong(Department of Medical Imaging,First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan Province 650032,China)
出处
《介入放射学杂志》
CSCD
北大核心
2019年第12期1211-1214,共4页
Journal of Interventional Radiology
关键词
肝恶性肿瘤
载药微球
经导管动脉化疗栓塞
malignant tumor of liver
drug-eluting beads
transcatheter arterial chemoembolization
